Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer
- PMID: 30786193
- DOI: 10.1056/NEJMe1816060
Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer
Comment in
-
Preventing Venous Thromboembolism in Patients with Cancer.N Engl J Med. 2019 May 30;380(22):2180-2181. doi: 10.1056/NEJMc1904003. N Engl J Med. 2019. PMID: 31141644 No abstract available.
Comment on
-
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.N Engl J Med. 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4. N Engl J Med. 2019. PMID: 30511879 Clinical Trial.
-
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
Similar articles
-
Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer.Eur Urol. 2020 Mar;77(3):388-390. doi: 10.1016/j.eururo.2019.10.019. Epub 2019 Nov 9. Eur Urol. 2020. PMID: 31718823 No abstract available.
-
[Thromboprophylaxis in patients with cancer].Internist (Berl). 2019 Sep;60(9):1004-1006. doi: 10.1007/s00108-019-0647-y. Internist (Berl). 2019. PMID: 31342090 Review. German. No abstract available.
-
Direct oral anticoagulants in cancer-associated venous thromboembolism: It is high time for a change of therapeutic paradigm.Cardiol J. 2020;27(4):347-349. doi: 10.5603/CJ.a2020.0067. Epub 2020 May 18. Cardiol J. 2020. PMID: 32419129 Free PMC article. No abstract available.
-
Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.Thromb Res. 2018 Apr;164 Suppl 1:S124-S129. doi: 10.1016/j.thromres.2018.01.018. Thromb Res. 2018. PMID: 29703470
-
Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.Drug Des Devel Ther. 2014 Nov 5;8:2181-91. doi: 10.2147/DDDT.S51006. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25395835 Free PMC article. Review.
Cited by
-
Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China.Front Pharmacol. 2024 Sep 23;15:1373333. doi: 10.3389/fphar.2024.1373333. eCollection 2024. Front Pharmacol. 2024. PMID: 39376608 Free PMC article.
-
Identification and validation of a novel 17 coagulation-related genes signature for predicting prognostic risk in colorectal cancer.Heliyon. 2024 Jun 7;10(12):e32687. doi: 10.1016/j.heliyon.2024.e32687. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38988584 Free PMC article.
-
Primary thromboprophylaxis in cancer outpatients - real-world evidence.J Thromb Thrombolysis. 2024 Jun;57(5):805-814. doi: 10.1007/s11239-024-02984-1. Epub 2024 Apr 20. J Thromb Thrombolysis. 2024. PMID: 38643312
-
Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive.Intern Emerg Med. 2023 Sep;18(6):1619-1634. doi: 10.1007/s11739-023-03306-8. Epub 2023 May 25. Intern Emerg Med. 2023. PMID: 37227679 Review.
-
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.J Clin Oncol. 2023 Jun 1;41(16):2911-2925. doi: 10.1200/JCO.22.00255. Epub 2023 Feb 2. J Clin Oncol. 2023. PMID: 36730884 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources